Report of the Council of Joint Stock Company "Olainfarm" for the regular meeting of shareholders


The Council of Joint Stock Company "Olainfarm" (hereinafter - the Company) is acquainted with the consolidated annual report and the group parent company report for the year 2019 prepared by the Board of the Company, together with the conclusion of the sworn auditors PricewaterhouseCoopers (hereinafter referred to as PWC) on this report. The Council has also assessed the financial situation of the Company and the work of the Board during the financial year 2019 and has prepared this report (hereinafter referred to as the Report).

The Council informs that the existing members of the Council were elected to the Council of the company at the shareholders' meeting of the company on April 1, 2019 and thus the Council in such structure in 2019 has been running for nine months. In the light of this, the Council makes its assessment of the first quarter of the financial year 2019 on the basis of the PWC report and information provided by the Company's Board, Audit Committee and other Company`s executives. The information contained in the Report describes the supervisory activities carried out by the Council from April 1, 2019.

In 2019 all performance indicators of the Company, its representative offices and dependent (subsidiary) companies (hereinafter – the Group) were better than in 2018. Total Group`s annual revenues in 2019 amounted to 137 million euros, which is 10 % more than in 2018. In turn, the gross profit was 85 mln. EUR, providing 10 mln. EUR increase. Gross margin profitability increased from 60 % in 2018 to 62 % in 2019. EBITDA figures also improved significantly in 2019 amounted to 33 mln. EUR. Group net profit in 2019 is 24 mln. EUR, that is more than 2 times higher than the annual net profit figures of the Company in 2018.

The overall financial position of the Group is stable. In 2019, the Company`s loan from financial institutions has been reduced by 31%. The ratio of net liabilities to EBITDA at the end of the year was 0,2. Financial stability is evidenced both by the balance of funds at the end of the year, which increased 5,6 times, and the available but unused amount of credit funds.

The performance of the Group in 2019 was significantly influenced by the evaluation and revision of the operational practices of previous periods, introducing additional control mechanisms and revaluation of concluded transactions and usual processes. As a result of such actions, in 2019 accruals in amount of 7 mln. EUR were created for the depreciation of various assets of the Group. Most of the impairment is based on assets that are not related to the production and distribution of pharmaceutical products, which is considered to be the main activity of the Group. In-depth activities carried out in 2019 in the analysis of operational, financial and legal risks are a good basis to move on, implementing a new strategy that defines the planned activities and objectives of the Group until 2025.

With the aim of focusing the activities of the Company to achieve a joint goal, a new corporate mission and vision was created.

Mission: we improve customers` lives and create value for our company by providing sustainable healthcare products and services through our expertise in manufacturing and sales.

Vision: Until 2025, we are among the top 10 largest Central and Eastern European manufacturers, which sustainably supply healthcare products and services in certain therapeutic areas — basically Central and Eastern Europe, CIS, as well as other global markets.

In 2019 the Company actively continued work on the program for renewal of the main product files, clarifying the necessary investments and setting a specific time frame for completing the research program. The investment program for restoring ready-made dosage forms will provide an opportunity to significantly expand operations in new markets, as well as improve sales opportunities in existing markets. The council would like to note that, in view of the pre-planned investments in research under the FARMA2020 program, changes have been made to the classification of the accounting of research costs, further placing the research expenditure as investments in line with the generally accepted practice of accounting for pharmaceutical companies.

Evaluation of activity of the Board

In 2019, significant activities were carried out by the Company’s Board, which ensured an increase in the Group's value. During the reporting period, the Group's operating processes in the main markets were reviewed, new practices were introduced in the implementation of product development, improved financial control and risk management. The activities carried out and the market situation ensure good financial results for the Group, which together with the available amount of funds allows the Board to prepare a dividend payment offer to shareholders in amount of 20% of the profit of the parent company corresponding to dividend policy approved in 2019 and amounts to 4 507 224,96 EUR or 0,32 EUR per share.

Taking into account the good performance, significant contribution to shareholders and Company’s established practice in accordance with which the Council determines to the Board the share of variable remuneration for the performance of the members of the Board, which is in line with the interests of the shareholders of the Company and contributes to the achievement of the Company's business objectives, subject to the principles and criteria set out in the shareholders' meeting regarding the determination of remuneration for Council members in paragraph 8.2 of the regulations No. AOR9.029.010/2 dated by 21.05.2018 “Regulations of procedure of the Board of the Joint Stock Company  “Olainfarm””, which provide that the total remuneration of the members of the Board and its distribution is determined by the Council, as well as the Council decides on the bonuses of the members of the Board, taking indicators of the Company as a basis of the performance; the Council supported the proposal of the Board to pay the bonus to the members of the Board in the amount of nine-month fixed monthly remuneration rate.

The Board, under the supervision of the Council, has actively worked on the development of a number of policies and procedures relevant to the management of the Company, which help to implement the principles of good governance. As one of the main challenges in the work of the Board, it is necessary to highlight the work with the subsidiaries of the Company and increasing the effectiveness of their management and operation. The Board has been active in arranging the financial planning and reporting process in subsidiaries.

Evaluation of the activities of the Audit committee

In 2019, the Audit Committee regularly informed the Council, submitted its reports on the inspections carried out and the facts, risks and problems identified.

Audit committee during the year 2019 paid attention, carried out visits, requested data on the activities of dependent companies (subsidiaries) and representative offices of the Company abroad, for example, in Ukraine, Uzbekistan, Azerbaijan, etc. Essential information was provided to the Council to improve the functioning and management of representative offices and dependent companies (subsidiaries), in particular in the area of investment, marketing expenditure, administrative expenditure planning, control and effectiveness control. The function of the Audit committee in monitoring the internal control system is highly important, especially in the period before the establishment of a professional internal audit team in the second half of 2019.

Council activities

The existing Council has held 35 meetings for the period from its election on April 1, 2019, and till December 31, 2019. Key tasks for the Council in 2019 was the improvement of the management system, and the strengthening of the internal control system. The Council's work was related to in-depth analysis of the Company's activities, achievement of the set goals, monitoring of the Group's financial results, formation of the Board, development of the new strategy and approval of management policies. From the Council's point of view, the activities carried out during the year 2019, were aimed at increasing the value of the Group, ensuring return to shareholders, as well as reducing the negative consequences caused by several extraordinary meetings of shareholders, with a view to changing the Company's management institutions, which clearly affects the view on the stability of the Company's management.

The Council has carried out a number of activities to create a professional and highly qualified Board of the Company. As the result of the tender, organized in cooperation with the international recruitment company “Amrop”, foreign pharmaceutical specialists Jeroen Hidde Weites and Elena Bushberg was attracted, as well as professionals from Latvia, who provide the necessary competences for the work of the Board. Several members of the Board were suspended as a result of both personal circumstances and deficiencies discovered in the course of their work.

The Council was actively involved in the development of the Company's strategy, which was crowned with the identification of new, focused development directions and development of the strategy, as well as the launch of implementation already in 2020. For the purpose of assessing the place and role of the Company in the global pharmaceutical market, in the summer of 2019, IQVIA, an international pharmaceutical consultant from the USA, was attracted to provide detailed data on the Company's main existing markets, key areas of therapies, competitors, and, crucially, prospective new markets and trends. The work started in 2018 on the restoration of the Company's leading products so-called registration documents, which would ensure their long-term realization in existing, as well as new markets, was evaluated In the strategy development process. The Eurasian Economic Union has decided on a gradual transition to a new common certification of pharmaceutical products throughout the Union, replacing the national certification, which will fully take effect in 2025. The product certification process directly affects the Company's sales in these markets. Renewal of certification is both financially and time-consuming. During the evaluation, a new and promising product portfolio was identified, which will create stable, effective opportunities to improve sales results in the future. In addition, it is positive that the renewed registration would pave the way for the conquest of new export markets also outside the Eurasian Economic Union.

The Council has proposed the development of a number of policies that streamline management processes. One of the most significant results for shareholders can be considered the participation of the Council in the creation and approval of the Dividend policy, which resulted in the dividend payment offer for the results of the year 2019, and determine a sustainable, transparent dividend policy which is understandable for shareholders in the future, as well.

COVID-19 has influenced the work of the Company indirectly. As one of the significant influences, we can characterize the decrease in purchasing power in proportion to the fall in GDP in the main markets of the Company. The influence of COVID-19 has led to fluctuations in demand due to social constraints that have changed the historical conditions for the operation of sales and promotion channels. There is uncertainty, that regulations and restrictions on medical procedures related to COVID-19 implemented in a number of countries, may impede the planning of clinical trials in the future. The Council, in cooperation with the Board, monitors the situation in the main markets so that the spread of COVID-19 does not leave a significant impact in achieving strategic objectives.

Together with the Board, the Council continues to work on improving the financing model of the Company's activities in order to optimize the financing of capital, borrowing, assets and development of the Company and the established strategy. In general, the Company continues to finance a significant part of its activities with capital and operating cash flow, but there are various other options and instruments, such as the issue of bonds, the use of financial instruments offered by the EU, etc.

Shareholders' meetings

Five shareholders' meetings have been convened during the reporting period, including the regular shareholders' meeting, which was held on June 17, 2019; and four extraordinary shareholder’s meetings have been convened – on April 1, June 21 and November 1, 2019, of which extraordinary shareholder meetings on November 1, 2019, have not been held due to lack of quorum.

The Council would like to thank the Board, all employees and partners of the Company for their cooperation in 2019, and wish a successful, stable and opportunities-rich year 2020!

In attachment:

- Annual report of the Audit committee


Joint Stock Company “Olainfarm”

Chairman of the Council,

Gundars Berzins

Additional information:

Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Ph.: +371 29178878


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease1.12.2020 22:01:00 CETPress release

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. The drug candidate or placebo will be administered for 52 weeks in up to 60 ADPKD patients with rapidly progressing disease. Patients will be randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary measures include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial is planned in 7 countries in Europe. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesi

REC Silicon – Cancellation of subsequent offering1.12.2020 20:13:46 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lysaker, 1 December 2020 Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement") and a potential subsequent offering (the "Subsequent Offering") of up to 18,518,518 new shares directed towards shareholders of the Company as of 14 October 2020 who were not allocated shares in the Private Placement. The Company has decided not to initiate the Subsequent Offering. The background for the cancellation is that the Company's shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription pric

Bombardier and Alstom Confirm Receipt of All Necessary Regulatory Approvals to Complete Bombardier Transportation Sale to Alstom1.12.2020 18:24:09 CETPress release

MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) and Alstom announced today that all necessary regulatory approvals required to complete the sale of Bombardier Transportation to Alstom have been received. Bombardier and Alstom now expect the transaction to close on January 29, 2021. About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are availab

FDA approves Xolair® (omalizumab) for adults with nasal polyps1.12.2020 18:07:00 CETPress release

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key d

Tecan raises forecast for the full year of 2020 based on continued extraordinary demand for COVID-19 related products1.12.2020 18:02:00 CETPress release

Sales growth now expected to be in the low to mid-teens percentage range in local currenciesReported EBITDA margin now forecasted above 20.5% of sales Männedorf, Switzerland, 1 December, 2020 – Based on the strong business performance year to date, as well as on the high order backlog and the continued elevated demand for COVID-19 related products, the Tecan Group (SIX Swiss Exchange: TECN) once again raised its outlook for full-year sales and reported EBITDA margin. These updated projections continue to be based on the assumptions that also for the remainder of the year supply chains and freight logistics remain undisrupted and all production sites stay fully operational. Based on continued strong demand for a number of product lines to help in the global fight against the coronavirus pandemic, Tecan now forecasts sales growth for full-year 2020 to be in the low to mid-teens percentage range in local currencies (latest guidance from August 12, 2020: “high single-digit percentage range

Touax: Successful asset refinancing - Containers Business1.12.2020 17:45:00 CETPress release

PRESS RELEASE Paris, December 1, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Successful asset refinancing - Containers Business Touax announces today that it has successfully refinanced asset-backed facilities of its Container division for a total of US$ 75 million, versus US$ 60 million previously, combining a Term Loan of US$ 37 million and a Revolving Credit Facility (RCF) of US$ 38 million with a two-year maturity. The documentation provides for an accordion option, allowing the line to be scaled up to US$ 85 million, to support growth. This operation allows the refinancing of the existing portfolio of assets as well as the financing of future investments. Touax Container Asset Finance Ltd will thus continue to invest for its development, particularly in the purchase of equipment for leasing purpose. Financing is granted by ABN AMRO Bank N.V., ING Belgium SA / NV and NIBC Bank N.V. Touax was advised by Stephenson Harwood (Legal Counsel). “We ar